Washington Bets Less Red Tape Speeds Cancer Care

Proposed rules aim to speed licensing and modernize radiation protection standards for medical isotopes.

28 Jul 2026

Regulators moved in late July, with the Nuclear Regulatory Commission publishing a proposed rule addressing barriers to medical use licensing, part of a broader deregulatory push affecting radiopharmaceutical sponsors and operators across the United States. The measure answers an executive order directing the agency to cut unnecessary regulatory burden and speed licensing timelines for medical and research applications, while still maintaining safety standards.

The rulemaking builds on an earlier May proposal that would eliminate decommissioning financial assurance requirements for radionuclides with half lives of 120 days or less, a category covering commonly used therapeutic isotopes including lutetium-177, yttrium-90, actinium-225 and radium-223. That change alone is projected to save industry, agreement states and the commission roughly $3 million.

A separate move landed on July 1, when the NRC proposed replacing its longstanding as low as reasonably achievable radiation protection principle with a more objective, risk informed, performance based framework. Existing occupational and public dose limits would stay intact, but licensees would demonstrate compliance differently, potentially simplifying radiation protection programs for hospitals and radiopharmacies.

Together, the rulemakings point to a sustained push to streamline the regulatory pathway just as clinical demand for targeted radiotherapies keeps climbing. For companies managing multi-site treatment programs, faster licensing and lighter financial assurance obligations could meaningfully lower the cost of expanding radioligand therapy access to new locations.